Digital
24th - 26th March 2021

8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)

The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 - 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. 

Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
 

WHAT TO EXPECT

Key Highlights

  • Biomarker Drug Discovery and Assay Development
  • Proteomics and Genomics based Biomarkers
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Commercialization of CDx
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Who Should Attend?

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery

CONFERENCE AGENDA
CLINICAL BIOMARKER IDENTIFICATION, QUALIFICATION AND PRECISION MEDICINE
TRANSLATIONAL AND CLINICAL BIOMARKER DRUG DISCOVERY AND ASSAY DEVELOPMENT
CONFERENCE SPEAKERS
Speakers
 Greg Kirchenbaum
Greg Kirchenbaum
Senior Scientist, Cellular Technology Limited, USA
George Pell
George Pell
CEO and Founder, Thirty-Six
Ginette Serrero
Ginette Serrero
Chief Executive Officer, Precision Antibody, USA
Zev Gechtman
Zev Gechtman
Ph.D. Technical Product Manager, Abcam
Keith Wharton
Keith Wharton
VP, Medical Director, Ultivue, USA
Mark Verardo
Mark Verardo
Senior Scientific Program Manager, Agilent Technologies, USA
Daniel Enderle
Daniel Enderle
Scientific Director, Companion Diagnostics, Exosome Diagnostics, Germany
Dr. Reinhard Ortmann
Dr. Reinhard Ortmann
Director Oncology & Precision Diagnostics, QIAGEN, Germany
SPONSORS
Platinium
example-image

Larvol

example-image

NeoGenomics

example-image

Agilent

example-image

QIAGEN

Gold
example-image

Owlstone Medical

example-image

Proteome Sciences

Silver
example-image

Abcam

Speaking Partner
example-image

Boston Healthcare

example-image

HTG Molecular Diagnostics, Inc.

example-image

Precision Antibody

example-image

Cellular Technology Limited

Meeting Partner
example-image

Burning Rock

PARTNERS
Media Partners
example-image

PharmaVOICE

example-image

PharmaTutor

example-image

Pharma Journalist

PAST EVENT GALLERY